US APPROVES EPIPEN COMPETITOR

The U.S. FDA has cleared Teva Pharmaceutical’s generic version of the life-saving allergy auto-injector several years after the Israeli drugmaker filed for approval. EpiPen, a product of Mylan NV, has been widely criticised for its exorbitant pricing. Mylan generates about $1 billion a year in EpiPen sales, after raising prices more than 100 per cent over the last decade.